

Curriculum Vitae of Guido Martignoni

Nato a Verona, 18 Luglio 1963

Attuale posizione lavorativa

Direttore del Dipartimento di Patologia, Ospedale Pederzoli, Peschiera del Garda, Verona
Professore Ordinario di Anatomia Patologica (MED/08), Università degli Studi di Verona.

Formazione universitaria

1988 – Laurea in Medicina, Università degli Studi di Verona

1992 - Abilitazione all'esercizio della professione di Medico, Università degli Studi di Verona

Posizioni e impiego

1992 Ricercatore di Anatomia Patologica, Università di Verona

2002 Professore Associato di Anatomia Patologica, Università di Sassari

2005-2019 Professore Associato di Anatomia Patologica, Università di Verona

2019-oggi Professore Ordinario di Anatomia Patologica, Università degli Studi di Verona, Italia

Onori

2015 Premio Medaglia Koss ISUP-USCAP Boston

Comitato Editoriale

Redazione:

1. Pathologica: Organo Ufficiale della SIAPEC (Società Italiana di Anatomia Patologica e Citologia)
2. Modern Pathology
3. Pathology
4. Gruppo di Lavoro: GIUP (Gruppo Italiano di UroAnatomia Patologica, segretario)
5. Membro del Comitato dell'Organizzazione Mondiale della Sanità sui Tumori del Sistema Genito-urinario nel 2002, 2016 e 2022

Attività scientifica

Focus di ricerca: Patologia Urogenitale, in particolare tumori renali. Oltre 330 pubblicazioni su riviste peer reviewed, indicizzate su Pubmed (H index 73)

researcher identifier ORCID: 0000-0002-7761-7274

Bibliografia (2013-2024):

1. Melisi D, Zecchetto C, Merz V, Malleo G, Landoni L, Quinzii A, Casalino S, Fazzini F, Gaule M, Pesoni C, Casetti L, Esposito A, Marchegiani G, Piazzola C, D'Onofrio M, de Robertis R, Gabbrielli A, Bernardoni L, Crino SF, Pietrobono S, Luchini C, Aliberti C, Martignoni G, Milleri S, Butturini G, Scarpa A, Salvia R, Bassi C. Perioperative NALIRIFOX in patients with resectable pancreatic ductal adenocarcinoma: The open-label, multicenter, phase II nITRO trial. *Eur J Cancer*. 2024 Jan;196:113430.
2. Melisi D, Zecchetto C, Merz V, Malleo G, Landoni L, Quinzii A, Casalino S, Fazzini F, Gaule M, Pesoni C, Casetti L, Esposito A, Marchegiani G, Piazzola C, D'Onofrio M, de Robertis R, Gabbrielli A, Bernardoni L, Crino SF, Pietrobono S, Luchini C, Aliberti C, Martignoni G, Milleri S, Butturini G, Scarpa A, Salvia R, Bassi C. Perioperative NALIRIFOX in patients with resectable pancreatic ductal adenocarcinoma: The open-label, multicenter, phase II nITRO trial. *Eur J Cancer*. 2024 Jan;196:113430.
3. Marletta S, Calìo A, Bogina G, Rizzo M, Brunelli M, Pedron S, Marcolini L, Stefanizzi L, Gobbo S, Princiotta A, Porta C, Pecoraro A, Antonelli A, Martignoni G. STING is a prognostic factor related to tumor necrosis, sarcomatoid dedifferentiation, and distant metastasis in clear cell renal cell carcinoma. *Virchows Arch*. 2023 Jul;483(1):87-96.
4. Calìo A, Marletta S, Settanni G, Rizzo M, Gobbo S, Pedron S, Stefanizzi L, Munari E, Brunelli M, Marcolini L, Pesci A, Fratoni S, Pierconti F, Raspollini MR, Marchetti A, Doglioni C, Amin MB, Porta C, Martignoni G. mTOR eosinophilic renal cell carcinoma: a distinctive tumor characterized by mTOR mutation, loss of chromosome 1, cathepsin-K expression, and response to target therapy. *Virchows Arch*. 2023 Dec;483(6):821-833.
5. Bao QR, Frigerio I, Tripepi M, Marletta S, Martignoni G, Giardino A, Regi P, Scopelliti F, Allegrini V, Girelli R, Pucciarelli S, Spolverato G, Butturini G. Prognostic value of major pathological response following neoadjuvant therapy for non resectable pancreatic ductal adenocarcinoma. *Pancreatology*. 2023 Apr;23(3):266-274.
6. Marletta S, Martignoni G, Ghimenton C, Stefanizzi L, Marcolini L, Calìo A. Well-differentiated neuroendocrine tumor of the urinary bladder expressing GATA 3. *Virchows Arch*. 2023 Apr;482(4):783-788.
7. Rizzo M, Calìo A, Brunelli M, Pezzicoli G, Ganini C, Martignoni G, Camillo P. Clinico-pathological implications of the 2022 WHO Renal Cell Carcinoma classification. *Cancer Treat Rev*. 2023 May;116:102558.
8. Calìo A, Marletta S, Brunelli M, Martignoni G. WHO 2022 Classification of Kidney Tumors: what is relevant? An update and future novelties for the pathologist. *Pathologica*. 2022 Feb;115(1):23-31.
9. Marletta S, Martignoni G, Ghimenton C, Stefanizzi L, Marcolini L, Calìo A. Well-differentiated neuroendocrine tumor of the urinary bladder expressing GATA 3. *Virchows Arch*. 2023 Apr;482(4):783-788.

10. D'Alterio C, Giardino A, Scognamiglio G, Butturini G, Portella L, Guardascione G, Frigerio I, Montella M, Gobbo S, Martignoni G, Napolitano V, De Vita F, Tatangelo F, Franco R, Scala S. CXCR4-CXCL12-CXCR7 and PD-1/PD-L1 in Pancreatic Cancer: CXCL12 Predicts Survival of Radically Resected Patients. *Cells*. 2022 Oct 22;11(21):3340.
11. Alaghebandan R, Agaimy A, Ali L, Alvarado-Cabrero I, Amin MB, Boudova L, Calìo A, Comperat EM, Damjanov I, Daum O, Farcas M, Gatalica Z, Gill AJ, Hartmann A, Hayes MM, Hora M, Kojima F, Kristiansen G, Kuroda N, López JI, Maclean F, Magi-Galluzzi C, Martignoni G, McKenney JK, Michalová K, Michal M, Mohanty SK, Netto GJ, Ohashi R, Ondiř O, Osunkoya AO, Gomez MDPM, Petersson F, Picken MM, Pivovarcikova K, Rogala J, Shah RB, Siadat F, Skenderi F, Sperga M, Suster SM, Svajdler M, Tretiakova M, Trpkov K, Ulamec M, Williamson SR, Yang XJ, Zhou M, Vranic S, Vujanic G, Michal M. A tribute to Prof. Ondrej Hes, MD, PhD (1968-2022). *Mod Pathol*. 2022 Dec;35(12):2023-2024.
12. Rizzo M, Pezzicoli G, Santoni M, Calìo A, Martignoni G, Porta C. MiT translocation renal cell carcinoma: A review of the literature from molecular characterization to clinical management. *Biochim Biophys Acta Rev Cancer*. 2022 Nov;1877(6):188823.
13. Ascione A, Martignoni G, d'Amati G, Della Rocca C, Graziano P, Pernazza A. Extremely late-onset pulmonary metastasis from uterine PEComa. *Pathologica*. 2022 Aug;114(4):312-315.
14. Calìo A, Marletta S, Brunelli M, Pedron S, Portillo SC, Segala D, Bariani E, Gobbo S, Netto G, Martignoni G. TFE3 and TFEB-rearranged renal cell carcinomas: an immunohistochemical panel to differentiate from common renal cell neoplasms. *Virchows Arch*. 2022 Dec;481(6):877-891.
15. Munari E, Querzoli G, Brunelli M, Marconi M, Sommaggio M, Cocchi MA, Martignoni G, Netto GJ, Calìo A, Quatrini L, Mariotti FR, Luchini C, Girolami I, Eccher A, Segala D, Ciompi F, Zamboni G, Moretta L, Bogina G. Comparison of three validated PD-L1 immunohistochemical assays in urothelial carcinoma of the bladder: interchangeability and issues related to patient selection. *Front Immunol*. 2022 Jul 27;13:954910.
16. Amin MB, McKenney JK, Martignoni G, Campbell SC, Pal S, Tickoo SK. Low grade oncocytic tumors of the kidney: a clinically relevant approach for the workup and accurate diagnosis. *Mod Pathol*. 2022 Oct;35(10):1306-1316.
17. Chilosi M, Doglioni C, Ravaglia C, Martignoni G, Salvagno GL, Pizzolo G, Bronte V, Poletti V. Unbalanced IDO1/IDO2 Endothelial Expression and Skewed Keyneurenine Pathway in the Pathogenesis of COVID-19 and Post-COVID-19 Pneumonia. *Biomedicines*. 2022 Jun 6;10(6):1332.
18. Calìo A, Cheng L, Martignoni G, Zhang S, Brunelli M, Eble JN. Mixed epithelial and stromal tumours of the kidney with malignant transformation: a clinicopathological study of four cases. *Pathology*. 2022 Oct;54(6):707-720.
19. Brunelli M, Martignoni G, Malpeli G, Volpe A, Cima L, Raspollini MR, Barbareschi M, Tafuri A, Masi G, Barzon L, Ammendola S, Villanova M, Cerruto MA, Milella M, Buti S,

- Bersanelli M, Fornarini G, Rebuzzi SE, Vellone VG, Gaggero G, Procopio G, Verzoni E, Bracarda S, Fanelli M, Sabbatini R, Passalacqua R, Perrucci B, Giganti MO, Donini M, Panni S, Tucci M, Prati V, Ortega C, Calìo A, Eccher A, Alongi F, Pappagallo G, Iacovelli R, Mosca A, Umari P, Montagnani I, Gobbo S, Atzori F, Munari E, Maruzzo M, Basso U, Pierconti F, Patriarca C, Colombo P, Lapini A, Conti G, Salvioni R, Bollito E, Cossarizza A, Massari F, Rizzo M, Franco R, Zito-Marino F, Aberasturi Plata Y, Galuppini F, Sbaraglia M, Fassan M, Dei Tos AP, Colecchia M, Moch H, Scaltriti M, Porta C, Delahunt B, Giannarini G, Bortolus R, Rescigno P, Banna GL, Signori A, Obispo MAL, Perris R, Antonelli A. Validation of a Novel Three-Dimensional (3D Fusion) Gross Sampling Protocol for Clear Cell Renal Cell Carcinoma to Overcome Intratumoral Heterogeneity: The Meet-Uro 18 Study. *J Pers Med*. 2022 Apr 30;12(5):727.
20. Ginori A, Spagnoli L, Pacetti P, Martignoni G, Cavazzana A. Carcinoma of Unknown Primary Site With Papillary Renal Cell Carcinoma Features and Without a Kidney Primary Lesion: A Diagnostic and Therapeutic Challenge. *Urology*. 2022 Jun;164:304-305.
 21. Munari E, Settanni G, Calìo A, Segala D, Lonardi S, Sandrini S, Vacca P, Tumino N, Marconi M, Brunelli M, Gobbo S, Netto GJ, Moretta L, Zamboni G, Martignoni G. TSC loss is a clonal event in eosinophilic solid and cystic renal cell carcinoma: a multiregional tumor sampling study. *Mod Pathol*. 2022 Mar;35(3):376-385.
 22. Brunelli M, Tafuri A, Cima L, Cerruto MA, Milella M, Zivi A, Buti S, Bersanelli M, Fornarini G, Vellone VG, Rebuzzi SE, Procopio G, Verzoni E, Bracarda S, Sabbatini R, Baldessari C, Eccher A, Passalacqua R, Perrucci B, Giganti MO, Donini M, Panni S, Tucci M, Prati V, Ortega C, Calìo A, Alongi F, Munari E, Pappagallo G, Iacovelli R, Mosca A, Porta C, Martignoni G, Antonelli A. MDM2 gene amplification as selection tool for innovative targeted approaches in PD-L1 positive or negative muscle-invasive urothelial bladder carcinoma. *J Clin Pathol*. 2022 Jan;75(1):39-44.
 23. Calìo A, Brunelli M, Marletta S, Zamboni G, Bonetti F, Pea M, Martignoni G. Epithelioid angiomylipoma: a pathological entity discovered in Verona with the endorsement of Doctor Rosai. *Pathologica*. 2021 Oct;113(5):307-315.
 24. Harada S, Calìo A, Janowski KM, Morlote D, Rodriguez Pena MD, Canete-Portillo S, Harbi D, DeFrank G, Magi-Galluzzi C, Netto GJ, Martignoni G, Mackinnon AC. Diagnostic utility of one-stop fusion gene panel to detect TFE3/TFEB gene rearrangement and amplification in renal cell carcinomas. *Mod Pathol*. 2021 Nov;34(11):2055-2063.
 25. Munari E, Marconi M, Querzoli G, Lunardi G, Bertoglio P, Ciompi F, Tosadori A, Eccher A, Tumino N, Quatrini L, Vacca P, Rossi G, Cavazza A, Martignoni G, Brunelli M, Netto GJ, Moretta L, Zamboni G, Bogina G. Impact of PD-L1 and PD-1 Expression on the Prognostic Significance of CD8⁺ Tumor-Infiltrating Lymphocytes in Non-Small Cell Lung Cancer. *Front Immunol*. 2021 May 26;12:680973.
 26. Calìo A, Brunelli M, Gobbo S, Argani P, Munari E, Netto G, Martignoni G. Cathepsin K: A Novel Diagnostic and Predictive Biomarker for Renal Tumors. *Cancers (Basel)*. 2021 May 18;13(10):2441.

27. Munari E, Mariotti FR, Quatrini L, Bertoglio P, Tumino N, Vacca P, Eccher A, Ciompi F, Brunelli M, Martignoni G, Bogina G, Moretta L. PD-1/PD-L1 in Cancer: Pathophysiological, Diagnostic and Therapeutic Aspects. *Int J Mol Sci.* 2021 May 12;22(10):5123.
28. Munari E, Settanni G, Calìo A, Segala D, Lonardi S, Sandrini S, Vacca P, Tumino N, Marconi M, Brunelli M, Gobbo S, Netto GJ, Moretta L, Zamboni G, Martignoni G. TSC loss is a clonal event in eosinophilic solid and cystic renal cell carcinoma: a multiregional tumor sampling study. *Mod Pathol.* 2021 May 14.
29. Ohashi R, Hartmann A, Martignoni G, Moch H. Re: Svetlana Avulova, John C. Cheville, Christine M. Lohse, et al. Grading Chromophobe Renal Cell Carcinoma: Evidence for a Four-tiered Classification Incorporating Coagulative Tumor Necrosis. *Eur Urol* 2021;79:225-31: Two-, Three-, or Four-tiered Grading of Chromophobe Renal Cancer: That's the Question! *Eur Urol.* 2021 Jul;80(1):e17-e18.
30. Chilosi M, Poletti V, Ravaglia C, Rossi G, Dubini A, Piciocchi S, Pedica F, Bronte V, Pizzolo G, Martignoni G, Doglioni C. The pathogenic role of epithelial and endothelial cells in early-phase COVID-19 pneumonia: victims and partners in crime. *Mod Pathol.* 2021 Aug;34(8):1444-1455.
31. Zito Marino F, Brunelli M, Rossi G, Calabrese G, Calìo A, Nardiello P, Martignoni G, Squire JA, Cheng L, Massi D, Franco R. Multitarget fluorescence in situ hybridization diagnostic applications in solid and hematological tumors. *Expert Rev Mol Diagn.* 2021 Feb;21(2):161-173.
32. Cirielli V, Bortolotti F, Cima L, De Battisti Z, Del Balzo G, De Salvia A, Laposata C, Raniero D, Vermiglio E, Portas M, Rodegher P, Ghimenton C, Martignoni G, Eccher A, Narayanasamy M, Vergine M, Turrina S, Tagliaro F, De Leo D, Brunelli M. Consultation between forensic and clinical pathologists for histopathology examination after forensic autopsy. *Med Sci Law.* 2021 Jan;61(1_suppl):25-35.
33. Calìo A, Brunelli M, Gobbo S, Pedron S, Segala D, Argani P, Martignoni G. Stimulator of interferon genes (STING) immunohistochemical expression in the spectrum of perivascular epithelioid cell (PEC) lesions of the kidney. *Pathology.* 2021 Aug;53(5):579-585
34. Calìo A, Harada S, Brunelli M, Pedron S, Segala D, Portillo SC, Magi- Galluzzi C, Netto GJ, Mackinnon AC, Martignoni G. TFEB rearranged renal cell carcinoma. A clinicopathologic and molecular study of 13 cases. Tumors harboring MALAT1-TFEB, ACTB-TFEB, and the novel NEAT1-TFEB translocations constantly express PDL1. *Mod Pathol.* 2021 Apr;34(4):842-850
35. Brunelli M, Tafuri A, Cima L, Cerruto MA, Milella M, Zivi A, Buti S, Bersanelli M, Fornarini G, Vellone VG, Rebuzzi SE, Procopio G, Verzoni E, Bracarda S, Sabbatini R, Baldessari C, Eccher A, Passalacqua R, Perrucci B, Giganti MO, Donini M, Panni S, Tucci M, Prati V, Ortega C, Calìo A, Alongi F, Munari E, Pappagallo G, Iacovelli R, Mosca A, Porta C, Martignoni G, Antonelli A. MDM2 gene amplification as selection tool for innovative targeted approaches in PD-L1 positive or negative muscle-invasive urothelial bladder carcinoma. *J Clin Pathol.* 2020 Nov 3;jclinpath-2020-207089.

36. Calìò A, Brunelli M, Segala D, Zamboni G, Bonetti F, Pea M, Martignoni G. Angiomyolipoma of the kidney: from simple hamartoma to complex tumour. *Pathology*. 2021 Jan;53(1):129-140.
37. Samaratunga H, Delahunt B, Srigley JR, Berney DM, Cheng L, Evans A, Furusato B, Leite KRM, MacLennan GT, Martignoni G, Moch H, Pan CC, Paner G, Ro J, Thunders M, Tsuzuki T, Wheeler T, van der Kwast T, Varma M, Williamson SR, Yaxley JW, Egevad L. Granular necrosis: a distinctive form of cell death in malignant tumours. *Pathology*. 2020 Aug;52(5):507-514.
38. Calìò A, Ammendola S, Brunelli M, Pedron S, Gobbo S, Martignoni G. Parvalbumin immunohistochemical expression in the spectrum of perivascular epithelioid cell (PEC) lesions of the kidney. *Virchows Arch*. 2021 Apr;478(4):785-791.
39. Rodriguez Pena MDC, Gordetsky J, Greipp PT, Wei S, Martignoni G, Netto GJ, Harada S, Prieto Granada CN. Rare MDM2 amplification in a fat-predominant angiomyolipoma. *Virchows Arch*. 2020 Nov;477(5):661-666.
40. Ohashi R, Martignoni G, Hartmann A, Calìò A, Segala D, Stöhr C, Wach S, Erlmeier F, Weichert W, Autenrieth M, Schraml P, Rupp NJ, Ohe C, Otsuki Y, Kawasaki T, Kobayashi H, Kobayashi K, Miyazaki T, Shibuya H, Usuda H, Umezu H, Fujishima F, Furusato B, Osakabe M, Sugai T, Kuroda N, Tsuzuki T, Nagashima Y, Ajioka Y, Moch H. Correction to: Multi-institutional re-evaluation of prognostic factors in chromophobe renal cell carcinoma: proposal of a novel two-tiered grading scheme. *Virchows Arch*. 2020 Mar;476(3):419-422.
41. Calìò A, Brunelli M, Segala D, Pedron S, Remo A, Ammendola S, Munari E, Pierconti F, Mosca A, Bollito E, Sidoni A, Fisogni S, Sacco C, Canu L, Sentinelli S, Fraccon AP, Fiorentino M, Scott C, Milella M, Porta C, Argani P, Martignoni G. Comprehensive analysis of 34 MiT family translocation renal cell carcinomas and review of the literature: investigating prognostic markers and therapy targets. *Pathology*. 2020 Apr;52(3):297-309.
42. 20: Giunchi F, Franceschini T, Gruppioni E, Altimari A, Capizzi E, Massari F, Schiavina R, Brunelli M, Martignoni G, Fiorentino M. Similarities and Differences between Clear Cell Tubulo-Papillary and Conventional Clear Cell Renal Cell Carcinoma: A Comparative Phenotypical and Mutational Analysis. *Diagnostics (Basel)*. 2020 Feb 23;10(2):123.
43. 21: Ohashi R, Martignoni G, Hartmann A, Calìò A, Segala D, Stöhr C, Wach S, Erlmeier F, Weichert W, Autenrieth M, Schraml P, Rupp NJ, Ohe C, Otsuki Y, Kawasaki T, Kobayashi H, Kobayashi K, Miyazaki T, Shibuya H, Usuda H, Umezu H, Fujishima F, Furusato B, Osakabe M, Sugai T, Kuroda N, Tsuzuki T, Nagashima Y, Ajioka Y, Moch H. Multi-institutional re-evaluation of prognostic factors in chromophobe renal cell carcinoma: proposal of a novel two-tiered grading scheme.
44. *Virchows Arch*. 2020 Mar;476(3):409-418.
45. 22: Eccher A, Girolami I, D'Errico A, Zaza G, Carraro A, Montin U, Boggi U, Scarpa A, Brunelli M, Martignoni G, Segev D, Rossi ED, Pantanowitz L. Management of Thyroid Nodules in Deceased Donors With Comparison Between Fine Needle Aspiration and Intraoperative Frozen Section in the Setting of Transplantation. *Prog Transplant*. 2019 Dec;29(4):316-320.

46. 23: Girolami I, Gambaro G, Ghimenton C, Beccari S, Calìo A, Brunelli M, Novelli L, Boggi U, Campani D, Zaza G, Boschiero L, López JI, Martignoni G, D'Errico A, Segev D, Neil D, Eccher A. Pre-implantation kidney biopsy: value of the expertise in determining histological score and comparison with the whole organ on a series of discarded kidneys. *J Nephrol*. 2020 eb;33(1):167-176.
47. 24: Calìo A, Segala D, Munari E, Brunelli M, Martignoni G. MiT Family Translocation Renal Cell Carcinoma: from the Early Descriptions to the Current Knowledge. *Cancers (Basel)*. 2019 Aug 3;11(8):1110.
48. 25: Di Nunno V, Mollica V, Brunelli M, Gatto L, Schiavina R, Fiorentino M, Santoni M, Montironi R, Calìo A, Eccher A, Milella M, Martignoni G, Brunocilla E, Massari F. A Meta-Analysis Evaluating Clinical Outcomes of Patients with Renal Cell Carcinoma Harboring Chromosome 9P Loss. *Mol Diagn Ther*. 2019 Oct;23(5):569-577
49. Delahunt B, Srigley JR, Judge M, Amin M, Billis A, Camparo P, Fleming S, Griffiths D, Lopez-Beltran A, Martignoni G, Moch H, Nacey JN, Zhou M, Evans AJ. Dataset for the reporting of renal biopsy for tumour: recommendations from the International Collaboration on Cancer Reporting (ICCR). *J Clin Pathol*. 2019 Sep;72(9):573-578.
50. 27: Vitale MG, Bracarda S, Cosmai L, Crocetti E, Di Lorenzo G, Lapini A, Mandressi A, Martorana G, Masini C, Montironi R, Ortega C, Passalacqua R, Porta C, Procopio G, Sepe P, Romano L, appagallo GL, Conti G, Guida M, Martignoni G, Nolè F, Pignata S, Gori S, Cartenì G. Management of kidney cancer patients: 2018 guidelines of the Italian Medical Oncology Association (AIOM). *Tumori*. 2019 Jul;105(4_suppl):3-12.
51. Iacovelli R, Ciccarese C, Brunelli M, Bogina G, Munari E, Bimbatti D, Mosillo C, Fantinel E, Bria E, Martignoni G, Tortora G. PD-L1 Expression in De Novo Metastatic Castration-sensitive Prostate Cancer. *J Immunother*. 2019 Sep;42(7):269-273.
52. Munari E, Zamboni G, Lunardi G, Marconi M, Brunelli M, Martignoni G, Netto GJ, Quatrini L, Vacca P, Moretta L, Bogina G. PD-L1 expression in non-small cell lung cancer: evaluation of the diagnostic accuracy of a laboratory-developed test using clone E1L3N in comparison with 22C3 and SP263 assays. *Hum Pathol*. 2019 Aug;90:54-59
53. Segala D, Gobbo S, Pesci A, Martignoni G, Santoro A, Angelico G, Arciuolo D, Spadola S, Valente M, Scambia G, Zannoni GF. Tamoxifen related Uterine Tumor Resembling Ovarian Sex Cord Tumor (UTROSCT): A case report and literature review of this possible association. *Pathol Res Pract*. 2019 May;215(5):1089-1092
54. Munari E, Zamboni G, Marconi M, Sommaggio M, Brunelli M, Martignoni G, Netto GJ, Moretta F, Mingari MC, Salgarello M, Terzi A, Picece V, Pomari C, Lunardi G, Cavazza A, Rossi G, Moretta L, Bogina G. Correction: PD-L1 expression heterogeneity in non-small cell lung cancer: evaluation of small biopsies reliability. *Oncotarget*. 2018 Dec 11;9(97):37077.
55. Munari E, Zamboni G, Sighele G, Marconi M, Sommaggio M, Lunardi G, Rossi G, Cavazza A, Moretta F, Gilioli E, Calìo A, Netto GJ, Hoque MO, Martignoni G, Brunelli M, Vacca P, Moretta L, Bogina G. Expression of programmed cell death ligand 1 in non-small cell lung cancer: Comparison between cytologic smears, core biopsies, and whole sections using the SP263 assay. *Cancer Cytopathol*. 2019 Feb;127(1):52-61.

56. Munari E, Calì A, Brunelli M, Martignoni G. Predicting progression in T1 non-muscle-invasive bladder cancer: back to histology. *BJU Int.* 2018 Dec;122(6):914-915.
57. Delahunt B, Srigley JR, Judge MJ, Amin MB, Billis A, Camparo P, Evans AJ, Fleming S, Griffiths DF, Lopez-Beltran A, Martignoni G, Moch H, Nacey JN, Zhou M. Data set for the reporting of carcinoma of renal tubular origin: recommendations from the International Collaboration on Cancer Reporting (ICCR). *Histopathology.* 2019 Feb;74(3):377-390.
58. 35: Riva G, Mian C, Luchini C, Girolami I, Ghimenton C, Cima L, Novelli L, Hanspeter E, Mazzoleni G, Schwienbacher C, Pycha S, D'Elia C, Trenti E, Pycha A, Martignoni G, Hes O, Eccher A, Nesi G, Brunelli M. Urachal carcinoma: from gross specimen to morphologic, immunohistochemical, and molecular analysis. *Virchows Arch.* 2019 Jan;474(1):13-20.
59. 36: Bimbatti D, Ciccarese C, Fantinel E, Sava T, Massari F, Bisogno I, Romano M, Porcaro A, Brunelli M, Martignoni G, Mazzarotto R, Artibani W, Tortora G, Iacovelli R. Predictive role of changes in the tumor burden and International Metastatic Renal Cell Carcinoma Database Consortium class during active surveillance for metastatic renal cell carcinoma. *Urol Oncol.* 2018 Dec;36(12):526.e13-526.e18.
60. 37: Calì A, Brunelli M, Segala D, Pedron S, Doglioni C, Argani P, Martignoni G. VEGFA amplification/increased gene copy number and VEGFA mRNA expression in renal cell carcinoma with TFE3 gene alterations. *Mod Pathol.* 2019 Feb;32(2):258-268
61. 38: Munari E, Zamboni G, Lunardi G, Marconi M, Sommaggio M, Brunelli M, Martignoni G, Netto GJ, Hoque MO, Moretta F, Mingari MC, Pegoraro MC, Mariotti FR, Vacca P, Moretta L, Bogina G. PD-L1 expression comparison between primary and relapsed non-small cell lung carcinoma using whole sections and clone SP263. *Oncotarget.* 2018 Jul 13;9(54):30465-30471. doi: 10.18632/oncotarget.25770.
62. 39: Munari E, Rossi G, Zamboni G, Lunardi G, Marconi M, Sommaggio M, Netto GJ, Hoque MO, Brunelli M, Martignoni G, Haffner MC, Moretta F, Pegoraro MC, Cavazza A, Samogin G, Furlan V, Mariotti FR, Vacca P, Moretta L, Bogina G. PD-L1 Assays 22C3 and SP263 are Not interchangeable in Non-Small Cell Lung Cancer When Considering Clinically Relevant Cutoffs: An Interclone Evaluation by Differently Trained Pathologists. *Am J Surg Pathol.* 2018 Oct;42(10):1384-1389.
63. 40: Williamson SR, Rao P, Hes O, Epstein JI, Smith SC, Picken MM, Zhou M, Tretiakova MS, Tickoo SK, Chen YB, Reuter VE, Fleming S, Maclean FM, Gupta NS, Kuroda N, Delahunt B, Mehra R, Przybycin CG, Cheng L, Eble JN, Grignon DJ, Moch H, Lopez JI, Kunju LP, Tamboli P, Srigley JR, Amin MB, Martignoni G, Hirsch MS, Bonsib SM, Trpkov K. Challenges in Pathologic Staging of Renal Cell Carcinoma: A Study of Interobserver Variability Among Urologic Pathologists. *Am J Surg Pathol.* 2018 Sep;42(9):1253-1261.
64. 41: Munari E, Zamboni G, Lunardi G, Marchionni L, Marconi M, Sommaggio M, Brunelli M, Martignoni G, Netto GJ, Hoque MO, Moretta F, Mingari MC, Pegoraro MC, Inno A, Paiano S, Terzi A, Cavazza A, Rossi G, Mariotti FR, Vacca P, Moretta L, Bogina G. PD-L1 Expression Heterogeneity in Non-Small Cell Lung Cancer: Defining Criteria for Harmonization between Biopsy Specimens and Whole Sections. *J Thorac Oncol.* 2018 Aug;13(8):1113-1120.

65. 42: Calìò A, Mengoli MC, Cavazza A, Rossi G, Ghimenton C, Brunelli M, Pea M, Chilosi M, Marcolini L, Martignoni G. Cathepsin K expression in clear cell "sugar" tumor (PEComa) of the lung. *Virchows Arch*. 2018 Jul;473(1):55-59.
66. Peta E, Sinigaglia A, Masi G, Di Camillo B, Grassi A, Trevisan M, Messa L, Loregian A, Manfrin E, Brunelli M, Martignoni G, Palù G, Barzon L. HPV16 E6 and E7 upregulate the histone lysine demethylase KDM2B through the c-MYC/miR-146a-5p axis. *Oncogene*. 2018 Mar;37(12):1654-1668.
67. Raspollini MR, Montagnani I, Montironi R, Castiglione F, Martignoni G, Cheng L, Lopez-Beltran A. Intratumoral heterogeneity may hinder precision medicine strategies in patients with clear cell renal cell carcinoma. *J Clin Pathol*. 2018 May;71(5):467-471.
68. Munari E, Zamboni G, Marconi M, Sommaggio M, Brunelli M, Martignoni G, Netto GJ, Moretta F, Mingari MC, Salgarello M, Terzi A, Picece V, Pomari C, Lunardi G, Cavazza A, Rossi G, Moretta L, Bogina G. PD-L1 expression heterogeneity in non-small cell lung cancer: evaluation of small biopsies reliability. *Oncotarget*. 2017 Oct 4;8(52):90123-90131. doi: 10.18632/oncotarget.21485. Erratum in: *Oncotarget*. 2018 Dec 11;9(97):37077.
69. Calìò A, Brunelli M, Segala D, Pedron S, Tardanico R, Remo A, Gobbo S, Meneghelli E, Doglioni C, Hes O, Zampini C, Argani P, Martignoni G. t(6;11) renal cell carcinoma: a study of seven cases including two with aggressive behavior, and utility of CD68 (PG-M1) in the differential diagnosis with pure epithelioid PEComa/epithelioid angiomyolipoma. *Mod Pathol*. 2018 Mar;31(3):474-487.
70. Calìò A, Eble JN, Hes O, Martignoni G, Harari SE, Williamson SR, Brunelli M, Osunkoya AO, Wang L, Comperat E, Lopez-Beltran A, Wang M, Zhang S, Curless KL, Post KM, Chang HY, Luchini C, Baldrige LA, MacLennan GT, Montironi R, Grignon DJ, Cheng L. Distinct clinicopathological features in metanephric adenoma harboring BRAF mutation. *Oncotarget*. 2016 Aug 8;8(33):54096-54105.
71. Porcaro AB, Siracusano S, de Luyk N, Corsi P, Sebben M, Tafuri A, Mattevi D, Bizzotto L, Tamanini I, Cerruto MA, Martignoni G, Brunelli M, Artibani W. Low-Risk Prostate Cancer and Tumor Upgrading in the Surgical Specimen: Analysis of Clinical Factors Predicting Tumor Upgrading in a Contemporary Series of Patients Who were Evaluated According to the Modified Gleason Score Grading System. *Curr Urol*. 2017 Aug;10(3):118-125.
72. Ciccarese C, Iacovelli R, Brunelli M, Massari F, Bimbatti D, Fantinel E, De Marco V, Porcaro AB, Martignoni G, Artibani W, Tortora G. Addressing the best treatment for non-clear cell renal cell carcinoma: A meta-analysis of randomised clinical trials comparing VEGFR-TKIs versus mTORi-targeted therapies. *Eur J Cancer*. 2017 Sep;83:237-246.
73. Egevad L, Cheville J, Evans AJ, Hörnblad J, Kench JG, Kristiansen G, Leite KRM, Magi-Galluzzi C, Pan CC, Samaratunga H, Srigley JR, True L, Zhou M, Clements M, Delahunt B; ISUP Pathology Imagebase Expert Panel. Pathology Imagebase-a reference image database for standardization of pathology. *Histopathology*. 2017 Nov;71(5):677-685.
74. Massari F, Ciccarese C, Hes O, Michal M, Calìò A, Fiorentino M, Giunchi F, D'Amuri A, Sanguedolce F, Sabbatini R, Guida A, Ardizzoni A, Porta C, Iacovelli R, Tortora G, Cima L, Ortega C, Lapini A, Martignoni G, Brunelli M. The Tumor Entity Denominated "clear cell-papillary renal cell carcinoma" According to the WHO 2016 new Classification, have the

Clinical Characters of a Renal Cell Adenoma as does Harbor a Benign Outcome. *Pathol Oncol Res.* 2018 Jul;24(3):447-456.

75. 52: Cacciamani G, Cima L, Ficial M, Novella G, Siracusano S, Tedeschi U, Balzarro M, Montin U, Cerruto MA, De Marco V, Porcaro AB, Hes O, D'Errico A, Martignoni G, Ghimenton C, Zaza G, Artibani W, Brunelli M, Eccher A. Liver Metastases From Renal Oncocytoma With Vascular Extension. *Appl Immunohistochem Mol Morphol.* 2019 May/Jun;27(5):e48-e53.
76. 53: Raspollini MR, Montagnani I, Montironi R, Cheng L, Martignoni G, Minervini A, Serni S, Nicita G, Carini M, Lopez-Beltran A. A contemporary series of renal masses with emphasis on recently recognized entities and tumors of low malignant potential: A report based on 624 consecutive tumors from a single tertiary center. *Pathol Res Pract.* 2017 Jul;213(7):804-808. doi: 10.1016/j.prp.2017.03.007. Epub 2017 Mar 12. PMID: 28554741.
77. 54: Ciccicarese C, Montironi R, Fiorentino M, Martignoni G, Brunelli M, Iacovelli R, Lopez-Beltran A, Cheng L, Scarpelli M, Moch H, Tortora G, Massari F. Circulating Tumor Cells: A Reliable Biomarker for Prostate Cancer Treatment Assessment? *Curr Drug Metab.* 2017;18(8):692-699.
78. 55: Posenato I, Calì A, Segala D, Sgroi S, Polara A, Brunelli M, Martignoni G. Primary seminal vesicle carcinoma. The usefulness of PAX8 immunohistochemical expression for the differential diagnosis. *Hum Pathol.* 2017 Nov;69:123-128.
79. 56: Williamson SR, Gadde R, Trpkov K, Hirsch MS, Srigley JR, Reuter VE, Cheng L, Kunju LP, Barod R, Rogers CG, Delahunt B, Hes O, Eble JN, Zhou M, McKenney JK, Martignoni G, Fleming S, Grignon DJ, Moch H, Gupta NS. Diagnostic criteria for oncocytic renal neoplasms: a survey of urologic pathologists. *Hum Pathol.* 2017 May;63:149-156. doi: 28315424.
80. 57: Brunelli M, Eccher A, Cima L, Trippini T, Pedron S, Chilosi M, Barbareschi M, Scarpa A, Pinna G, Cabrini G, Pilotto S, Carbognin L, Bria E, Tortora G, Fioravanzo A, Schiavo N, Meglio M, Sava T, Belli L, Martignoni G, Ghimenton C. Next-generation repeat-free FISH probes for DNA amplification in glioblastoma in vivo: Improving patient selection to MDM2-targeted inhibitors. *Cancer Genet.* 2017 Jan;210:28-33.
81. 58: Smith SC, Sirohi D, Ohe C, McHugh JB, Hornick JL, Kalariya J, Karia S, Snape K, Hodgson SV, Cani AK, Hovelson D, Luthringer DJ, Martignoni G, Chen YB, Tomlins SA, Mehra R, Amin MB. A distinctive, low-grade oncocytic fumarate hydratase-deficient renal cell carcinoma, orphologically reminiscent of succinate dehydrogenase-deficient renal cell carcinoma. *Histopathology.* 2017 Jul;71(1):42-52.
82. 59: Munari E, Cima L, Massari F, Bertoldo F, Porcaro AB, Calì A, Riva G, Ciocchetta E, Ciccicarese C, Modena A, Iacovelli R, Sava T, Eccher A, Ghimenton C, Tortora G, Artibani W, Novella G, Bogina G, Zamboni G, Sanguedolce F, D'Amuri A, Martignoni G, Brunelli M. Cathepsin K expression in castration-resistant prostate carcinoma: a therapeutical target for patients at risk for bone metastases. *Int J Biol Markers.* 2017 May 4;32(2):e243-e247.
83. Calì A, Bria E, Pilotto S, Gilioli E, Nottegar A, Eccher A, Cima L, Santo A, Pedron S, Turri G, Knuutila S, Chilosi M, Vanzo F, Bogina G, Terzi A, Tortora G, Scarpa A, Loda M,

- Martignoni G, Brunelli M. ALK gene copy number in lung cancer: Unspecific polyploidy versus specific amplification visible as double minutes. *Cancer Biomark.* 2017;18(2):215-220.
87. Martignoni G, Brunelli M, Segala D, Munari E, Gobbo S, Cima L, Borze I, Wirtanen T, Sarhadi VK, Atanesyan L, Savola S, Barzon L, Masi G, Fassan M, Eble JN, Bohling T, Cheng L, Delahunt B, Knuutila S. Validation of 34betaE12 immunoexpression in clear cell papillary renal cell carcinoma as a sensitive biomarker. *Pathology.* 2017 Jan;49(1):10-18
88. Eccher A, Boschiero L, Delahunt B, Cima L, Fior F, Nacchia F, Rostand M, Carraro A, Tedeschi U, Zaza G, Casartelli Liviero M, Zampicini L, Chilosi M, Feltrin G, Rago C, D'Errico A, Ghimenton C, Martignoni G, Brunelli M. De Novo Renal Neoplasia After Kidney Transplantation According to New 2016 WHO Classification of Renal Tumors. *Ann Transplant.* 2016 Dec
89. Kouba EJ, Eble JN, Simper N, Grignon DJ, Wang M, Zhang S, Wang L, Martignoni G, Williamson SR, Brunelli M, Luchini C, Calió A, Cheng L. High fidelity of driver chromosomal alterations among primary and metastatic renal cell carcinomas: implications for tumor clonal evolution and treatment. *Mod Pathol.* 2016 Nov;29(11):1347-1357
90. Raspollini MR, Luque RJ, Menendez CL, Bollito E, Brunelli M, Martignoni G, Montironi R, Cheng L, Blanca A, Baroni G, Minervini A, Lopez-Beltran A. T1 high- grade bladder carcinoma outcome: the role of p16, topoisomerase-II α , survivin, and E-cadherin. *Hum Pathol.* 2016 Nov;57:78-84.
91. Fiorentino M, Gruppioni E, Massari F, Giunchi F, Altimari A, Ciccarese C, Bimbatti D, Scarpa A, Iacovelli R, Porta C, Virinder S, Tortora G, Artibani W, Schiavina R, Ardizzoni A, Brunelli M, Knuutila S, Martignoni G. Wide spetcrum mutational analysis of metastatic renal cell cancer: a retrospective next generation sequencing approach. *Oncotarget.* 2017 Jan 31;8(5):7328-7335.
92. Perico ME, Grasso S, Brunelli M, Martignoni G, Munari E, Moiso E, Fracasso G, Cestari T, Naim HY, Bronte V, Colombatti M, Ramarli D. Prostate-specific membrane antigen (PSMA) assembles a macromolecular complex regulating growth and survival of prostate cancer cells "in vitro" and correlating with progression "in vivo". *Oncotarget.* 2016 Nov 8;7(45):74189-74202.
93. Brunelli M, Erdini F, Cima L, Eccher A, Fioravanzo A, Gobbo S, Segala D, Ghimenton C, Mazzoleni G, Munari E, Carella R, Martignoni G. Proximal CD13 Versus Distal GATA-3 xpression in Renal Neoplasia According to WHO 2016 Classification. *Appl Immunohistochem Mol Morphol.* 2018 May/Jun;26(5):316-323.
94. Modena A, Iacovelli R, Scarpa A, Brunelli M, Ciccarese C, Fantinel E, Bimbatti D, Massari F, Martignoni G, Tortora G. Investigating BRCA Mutations: A Breakthrough in Precision Medicine of Castration-Resistant Prostate Cancer. *Target Oncol.* 2016 Oct;11(5):569-577.
95. Raspollini MR, Castiglione F, Martignoni G, Lapini A, Cheng L, Montironi R, Lopez-Beltran A. Multiple and bilateral kidney tumors with clear cells of three different histotypes: A case report with clinicopathologic and molecular study. *APMIS.* 2016 Jul;124(7):619-623.

96. Porcaro AB, Siracusano S, De Luyk N, Corsi P, Sebben M, Tafuri A, Bizzotto L, Tamanini I, Inverardi D, Cerruto MA, Martignoni G, Brunelli M, Artibani W. Low-Risk Prostate Cancer and Tumor Upgrading to Higher Patterns in the Surgical Specimen. Analysis of Clinical Factors Predicting Tumor Upgrading to Higher Gleason Patterns in a Contemporary Series of Patients Who Have Been Evaluated According to the Modified Gleason Score Grading System. *Urol Int.*2016;97(1):32-41.
97. Delahunt B, Egevad L, Samaratunga H, Martignoni G, Nacey JN, Srigley JR. Reply: Gleason and Fuhrman no longer make the grade. *Histopathology.* 2016 Aug;69(2):341-2. doi: 10.1111/his.12947. Epub 2016 Apr 5. PMID: 26989872.
98. Bailey P, Chang DK, Nones K, Johns AL, Patch AM, Gingras MC, Miller DK, Christ AN, Bruxner TJ, Quinn MC, Nourse C, Murtaugh LC, Harliwong I, Idrisoglu S, Manning S, Nourbakhsh E, Wani S, Fink L, Holmes O, Chin V, Anderson MJ, Kazakoff S, Leonard C, Newell F, Waddell N, Wood S, Xu Q, Wilson PJ, Cloonan N, Kassahn KS, Taylor D, Quek K, Robertson A, Pantano L, Mincarelli L, Sanchez LN, Evers L, Wu J, Pinese M, Cowley MJ, Jones MD, Colvin EK, Nagrial AM, Humphrey ES, Chantrell LA, Mawson A, Humphris J, Chou A, Pajic M, Scarlett CJ, Pinho AV, Giry-Laterriere M, Rooman I, Samra JS, Kench JG, Lovell JA, Merrett ND, Toon CW, Epari K, Nguyen NQ, Barbour A, Zeps N, Moran-Jones K, Jamieson NB, Graham JS, Duthie F, Oien K, Hair J, Grützmann R, Maitra A, Iacobuzio-Donahue CA, Wolfgang CL, Morgan RA, Lawlor RT, Corbo V, Bassi C, Rusev B, Capelli P, Salvia R, Tortora G, Mukhopadhyay D, Petersen GM; Australian Pancreatic Cancer Genome Initiative, Munzy DM, Fisher WE, Karim SA, Eshleman JR, Hruban RH, Pilarsky C, Morton JP, Sansom OJ, Scarpa A, Musgrove EA, Bailey UM, Hofmann O, Sutherland RL, Wheeler DA, Gill AJ, Gibbs RA, Pearson JV, Waddell N, Biankin AV, Grimmond SM. Genomic analyses identify molecular subtypes of pancreatic cancer. *Nature.* 2016 Mar 3;531(7592):47-52.
99. Modena A, Massari F, Ciccarese C, Brunelli M, Santoni M, Montironi R, Martignoni G, Tortora G. Targeting Met and VEGFR Axis in Metastatic Castration- Resistant Prostate Cancer: 'Game Over'? *Target Oncol.* 2016 Aug;11(4):431-46.
100. Ciccarese C, Santoni M, Brunelli M, Buti S, Modena A, Nabissi M, Artibani W, Martignoni G, Montironi R, Tortora G, Massari F. AR-V7 and prostate cancer: The watershed for treatment selection? *Cancer Treat Rev.* 2016 Feb;43:27-35.
101. Rosati G, Ambrosini G, Barni S, Andreoni B, Corradini G, Luchena G, Daniele B, Gaion F, Oliverio G, Duro M, Martignoni G, Pinna N, Sozzi P, Pancera G, Solina G, Pavia G, Pignata S, Johnson F, Labianca R, Apolone G, Zaniboni A, Monteforte M, Negri E, Torri V, Mosconi P, Fossati R; GILDA working group. A randomized trial of intensive versus minimal surveillance of patients with resected Dukes B2-C colorectal carcinoma. *Ann Oncol.* 2016 Feb;27(2):274-80.
102. Massari F, Ciccarese C, Calì A, Munari E, Cima L, Porcaro AB, Novella G, Artibani W, Sava T, Eccher A, Ghimenton C, Bertoldo F, Scarpa A, Sperandio N, Porta C, Bronte V, Chilosì M, Bogina G, Zamboni G, Tortora G, Samaratunga H, Martignoni G, Brunelli M. Magnitude of PD-1, PD-L1 and T Lymphocyte Expression on Tissue from Castration-Resistant Prostate Adenocarcinoma: An Exploratory Analysis. *Target Oncol.* 2016 Jun;11(3):345-51.

103. Eccher A, Neil D, Ciangherotti A, Cima L, Boschiero L, Martignoni G, Ghimenton C, Chilosi M, Giobelli L, Zampicini L, Casartelli M, Brunelli M. Digital reporting of whole-slide images is safe and suitable for assessing organ quality in preimplantation renal biopsies. *Hum Pathol.* 2016 Jan;47(1):115-20.
104. Massari F, Ciccarese C, Bria E, Porta C, La Russa F, Knuutila S, Artibani W, Porcaro AB, Bimbatti D, Modena A, Sava T, Tortora G, Cheng L, Eccher A, Cima L, Pedron S, Ghimenton C, Martignoni G, Brunelli M. Reprofile Metastatic Samples for Chromosome 9p and 14q Aberrations as a Strategy to Overcome Tumor Heterogeneity in Clear-cell Renal Cell Carcinoma. *Appl Immunohistochem Mol Morphol.* 2017 Jan;25(1):39-43.
105. Raspollini MR, Castiglione F, Martignoni G, Cheng L, Montironi R, Lopez- Beltran A. Unlike in clear cell renal cell carcinoma, KRAS is not mutated in multilocular cystic clear cell renal cell neoplasm of low potential. *Virchows Arch.* 2015 Dec;467(6):687-693.
106. Porcaro AB, Novella G, Balzarro M, Martignoni G, Brunelli M, Cacciamani G, Cerruto MA, Artibani W. Prostate chronic inflammation type IV and prostate cancer risk in patients undergoing first biopsy set: Results of a large cohort study. *Asian J Urol.* 2015 Oct;2(4):224-232.
107. Brunelli M, Nottegar A, Bogina G, Calì A, Cima L, Eccher A, Vicentini C, Marcolini L, Scarpa A, Pedron S, Brunello E, Knuutila S, Sapino A, Marchiò C, Bria E, Molino A, Carbognin L, Tortora G, Jasani B, Miller K, Merdol I, Zanatta L, Laurino L, Wirtanen T, Zamboni G, Marconi M, Chilosi M, Manfrin E, Martignoni G, Bonetti F. Monosomy of chromosome 17 in breast cancer during interpretation of HER2 gene amplification. *Am J Cancer Res.* 2015 Jun 15;5(7):2212-21.
108. Delahunt B, Egevad L, Samaratunga H, Martignoni G, Nacey JN, Srigley JR. Gleason and Fuhrman no longer make the grade. *Histopathology.* 2016 Mar;68(4):475-81.
109. Kinney SN, Eble JN, Hes O, Williamson SR, Grignon DJ, Wang M, Zhang S, Baldrige LA, Martignoni G, Brunelli M, Wang L, Comperat E, Fan R, Montironi R, MacLennan GT, Cheng L. Metanephric adenoma: the utility of immunohistochemical and cytogenetic analyses in differential diagnosis, including solid variant papillary renal cell carcinoma and epithelial-predominant nephroblastoma. *Mod Pathol.* 2015 Sep;28(9):1236-48.
110. Massari F, Bria E, Ciccarese C, Munari E, Modena A, Zamboni V, Sperduti I, Artibani W, Cheng L, Martignoni G, Tortora G, Brunelli M. Prognostic Value of Beta-Tubulin-3 and c-Myc in Muscle Invasive Urothelial Carcinoma of the Bladder. *PLoS One.* 2015 Jun 5;10(6):e0127908.
111. Martignoni G, Pea M, Zampini C, Brunelli M, Segala D, Zamboni G, Bonetti F. PEComas of the kidney and of the genitourinary tract. *Semin Diagn Pathol.* 2015 Mar;32(2):140-59.
112. Scambi C, Ugolini S, Jokiranta TS, De Franceschi L, Bortolami O, La Verde V, Guarini P, Caramaschi P, Ravagnani V, Martignoni G, Colato C, Pedron S, Benedetti F, Sorio M, Poli F, Biasi D. The local complement activation on vascular bed of patients with systemic sclerosis: a hypothesis-generating study. *PLoS One.* 2015 Feb 6;10(2):e0114856.

113. Massari F, Ciccarese C, Santoni M, Brunelli M, Conti A, Modena A, Montironi R, Santini D, Cheng L, Martignoni G, Cascinu S, Tortora G. The route to personalized medicine in bladder cancer: where do we stand? *Target Oncol.* 2015 Sep;10(3):325-36.
114. Massari F, Santoni M, Ciccarese C, Santini D, Alfieri S, Martignoni G, Brunelli M, Piva F, Berardi R, Montironi R, Porta C, Cascinu S, Tortora G. PD-1 blockade therapy in renal cell carcinoma: current studies and future promises. *Cancer Treat Rev.* 2015 Feb;41(2):114-21.
115. Massari F, Ciccarese C, Bimbatti D, Fantinel E, Modena A, Simbolo M, Brunelli M, Artibani W, Martignoni G, Scarpa A, Tortora G. Complete remission with sunitinib in a poor-risk patient with metastatic renal cell carcinoma: the fine balance between toxicity and efficacy. *Anticancer Drugs.* 2015 Apr;26(4):469-73.
116. Brunelli M, Beccari S, Colombari R, Gobbo S, Giobelli L, Pellegrini A, Chilosi M, Lunardi M, Martignoni G, Scarpa A, Eccher A. iPathology cockpit diagnostic station: validation according to College of American Pathologists Pathology and Laboratory Quality Center recommendation at the Hospital Trust and University of Verona. *Diagn Pathol.* 2014;9 Suppl 1(Suppl 1):S12.
117. Fiorini C, Massari F, Pedron S, Sanavio S, Ciccarese C, Porcaro AB, Artibani W, Bertoldo F, Zampini C, Sava T, Ficial M, Calì A, Chilosi M, D'Amuri A, Sanguedolce F, Tortora G, Scarpa A, Delahunt B, Porta C, Martignoni G, Brunelli M. Methods to identify molecular expression of mTOR pathway: a rationale approach to stratify patients affected by clear cell renal cell carcinoma for more likely response to mTOR inhibitors. *Am J Cancer Res.* 2014 Nov 19;4(6):907-15.
118. Rioux-Leclercq N, Ferran A, Mahul A, Argani P, Billis A, Bonsib S, Cheng L, Cheville J, Eble J, Egevad L, Epstein J, Grignon D, Hes O, Humphrey P, Magi-Galluzzi C, Martignoni G, McKenney J, Merino M, Moch H, Montironi R, Netto G, Reuter V, Samaratunga H, Shen S, Srigley J, Amboli P, Tan PH, Tickoo S, Trpkov K, Zhou M, Delahunt B, Comperat E; International Society of Urologic Pathology. Les tumeurs rénales : recommandations de la conférence de consensus de l'International Society of Urologic Pathology (ISUP) 2012 [Renal tumors: The International Society of Urologic Pathology (ISUP) 2012 consensus conference recommendations]. *Ann Pathol.* 2014 Dec;34(6):448-61. French.
119. Liang N, Zhang C, Dill P, Panasyuk G, Pion D, Koka V, Gallazzini M, Olson EN, Lam H, Henske EP, Dong Z, Apte U, Pallet N, Johnson RL, Terzi F, Kwiatkowski DJ, Scoazec JY, Martignoni G, Pende M. Regulation of YAP by mTOR and autophagy reveals a therapeutic target of tuberous sclerosis complex. *J Exp Med.* 2014 Oct 20;211(11):2249-63.
120. Perino G, Ricciardi BF, Jerabek SA, Martignoni G, Wilner G, Maass D, Goldring SR, Purdue PE. Implant based differences in adverse local tissue reaction in failed total hip arthroplasties: a morphological and immunohistochemical study. *BMC Clin Pathol.* 2014 Sep 5;14:39.
121. Massari F, Ciccarese C, Porcaro AB, Ferrero S, Gazzano G, Artibani W, Modena A, Bria E, Sava T, Calì A, Novara G, Ficarra V, Chilosi M, Martignoni G, Bosari S, Cheng L, Tortora G, Brunelli M. Quantitative score modulation of HSP90 and HSP27 in clear cell renal cell carcinoma. *Pathology.* 2014 Oct;46(6):523-6.

122. Porcaro AB, Novella G, Molinari A, Terrin A, Minja A, De Marco V, Martignoni G, Brunelli M, Cerruto MA, Curti P, Cavalleri S, Artibani W. Prostate volume index and chronic inflammation of the prostate type IV with respect to the risk of prostate cancer. *Urol Int*. 2015;94(3):270-85.
123. Eccher A, Boschiero L, Fior F, Casartelli Liviero M, Zampicini L, Ghimenton C, D'Errico-Grigioni A, Calì A, Martignoni G, Delahunt B, Brunelli M. Donor kidneys with miliary papillary renal cell neoplasia: the role of the pathologist in determining suitability for transplantation. *Ann Transplant*. 2014 Jul 24;19:362-6
124. Delahunt B, Samaratunga H, Martignoni G, Srigley JR, Evans AJ, Brunelli M. Percutaneous renal tumour biopsy. *Histopathology*. 2014 Sep;65(3):295-308.
125. DE Marco V, Cerruto MA, D'Elia C, Brunelli M, Otte O, Minja A, Luchini C, Novella G, Cavalleri S, Martignoni G, Artibani W. Prognostic role of substaging in T1G3 transitional cell carcinoma of the urinary bladder. *Mol Clin Oncol*. 2014 Jul;2(4):575-580.
126. Shuch B, Amin A, Armstrong AJ, Eble JN, Ficarra V, Lopez-Beltran A, Martignoni G, Rini BI, Kutikov A. Understanding pathologic variants of renal cell carcinoma: distilling therapeutic opportunities from biologic complexity. *Eur Urol*. 2015 Jan;67(1):85-97.
127. Amin MB, Smith SC, Agaimy A, Argani P, Compérat EM, Delahunt B, Epstein JI, Eble JN, Grignon DJ, Hartmann A, Hes O, Hirsch MS, Jimenez RE, Kunju LP, Martignoni G, McKenney JK, Moch H, Montironi R, Paner GP, Rao P, Srigley JR, Tickoo SK, Reuter VE. Collecting duct carcinoma versus renal medullary carcinoma: an appeal for nosologic and biological clarity. *Am J Surg Pathol*. 2014 Jul;38(7):871-4.
128. Calì A, Nottesgar A, Gilioli E, Bria E, Pilotto S, Peretti U, Kinspergher S, Simionato F, Pedron S, Knuutila S, Tortora G, Eccher A, Santo A, Tondulli L, Inghirami G, Tabbò F, Martignoni G, Chilosi M, Scarpa A, Brunelli M. ALK/EML4 fusion gene may be found in pure squamous arcinoma of the lung. *J Thorac Oncol*. 2014 May;9(5):729-32.
129. Migliorini F, Baldassarre R, Artibani W, Martignoni G, Brunelli M. Rare case of intra-testicular adenomatoid tumour. *Arch Ital Urol Androl*. 2014 Mar 28;86(1):44-5.
130. Munari E, Marchionni L, Chitre A, Hayashi M, Martignoni G, Brunelli M, Gobbo S, Argani P, Allaf M, Hoque MO, Netto GJ. Clear cell papillary renal cell carcinoma: micro-RNA expression profiling and comparison with clear cell renal cell carcinoma and papillary renal cell carcinoma. *Hum Pathol*. 2014 Jun;45(6):1130-8.
131. Massari F, Ciccarese C, Modena A, Maines F, Segala D, Luchini C, Marcolini L, Cavicchioli F, Cavalleri S, Bria E, Brunelli M, Martignoni G, Artibani W, Tortora G. Adenocarcinoma of the paraurethral glands: a case report. *Histol Histopathol*. 2014 Oct;29(10):1295-303
132. Aitini E, Martignoni G, Labianca R; Italian Group for the study of Digestive Tract Cancer (GISCAD). Communication models for doctor-patient relationships. *J Cancer Educ*. 2014 Jun;29(2):211-2.
133. Chilosi M, Facchetti F, Calì A, Zamò A, Brunelli M, Martignoni G, Rossi A, Montagna L, Piccoli P, Dubini A, Tironi A, Tomassetti S, Poletti V, Doglioni C. Oncogene-induced senescence

distinguishes indolent from aggressive forms of pulmonary and non-pulmonary Langerhans cell histiocytosis. *Leuk Lymphoma*. 2014 Nov;55(11):2620-6

134. Ellis CL, Eble JN, Subhawong AP, Martignoni G, Zhong M, Ladanyi M, Epstein JI, Netto GJ, Argani P. Clinical heterogeneity of Xp11 translocation renal cell carcinoma: impact of fusion subtype, age, and stage. *Mod Pathol*. 2014 Jun;27(6):875-86.
135. Martignoni G, Brunelli M, Segala D, Gobbo S, Borze I, Atanesyan L, Savola S, Barzon L, Masi G, Tardanico R, Zhang S, Eble JN, Chilosi M, Böhlting T, Cheng L, Delahunt B, Knuutila S. Renal cell carcinoma with smooth muscle stroma lacks chromosome 3p and VHL alterations. *Mod Pathol*. 2014 May;27(5):765-74.
136. Williamson SR, MacLennan GT, Lopez-Beltran A, Montironi R, Tan PH, Martignoni G, Grignon DJ, Eble JN, Idrees MT, Scarpelli M, Cheng L. Cystic partially regressed clear cell renal cell carcinoma: a potential mimic of multilocular cystic renal cell carcinoma. *Histopathology*. 2013 Dec;63(6):767-79.
137. Tan PH, Cheng L, Rioux-Leclercq N, Merino MJ, Netto G, Reuter VE, Shen SS, Grignon DJ, Montironi R, Egevad L, Srigley JR, Delahunt B, Moch H; ISUP Renal Tumor Panel. Renal tumors: diagnostic and prognostic biomarkers. *Am J Surg Pathol*. 2013 Oct;37(10):1518-31.
138. Trpkov K, Grignon DJ, Bonsib SM, Amin MB, Billis A, Lopez-Beltran A, Samarasinghe H, Tamboli P, Delahunt B, Egevad L, Montironi R, Srigley JR; members of the ISUP Renal Tumor Panel. Handling and staging of renal cell carcinoma: the International Society of Urological Pathology Consensus (ISUP) conference recommendations. *Am J Surg Pathol*. 2013 Oct;37(10):1505-17.
139. Delahunt B, Cheville JC, Martignoni G, Humphrey PA, Magi-Galluzzi C, McKenney J, Egevad L, Algaba F, Moch H, Grignon DJ, Montironi R, Srigley JR; Members of the ISUP Renal Tumor Panel. The International Society of Urological Pathology (ISUP) grading system for renal cell carcinoma and other prognostic parameters. *Am J Surg Pathol*. 2013 Oct;37(10):1490-504.
140. Srigley JR, Delahunt B, Eble JN, Egevad L, Epstein JI, Grignon DJ, Hes O, Moch H, Montironi R, Tickoo SK, Zhou M, Argani P; ISUP Renal Tumor Panel. The International Society of Urological Pathology (ISUP) Vancouver Classification of Renal Neoplasia. *Am J Surg Pathol*. 2013 Oct;37(10):1469-89.
141. Brunelli M, Manfrin E, Bria E, Massari F, Tortora G, Brunello E, Carbognin L, Nottegar A, Furlanetto J, Molino A, Fiorio E, Chilosi M, Jasani B, Vergine M, Marcolini L, Filippini D, Scarpa A, Martignoni G, Bonetti F; Members of Veneto Region - Pathology Screening Group. HER2/neu gene determination in women screened for breast carcinoma: how screening programs reduce the skyrocketing cost of targeted therapy. *Anticancer Res*. 2013 Sep;33(9):3705-10.
142. Brunello E, Bogina G, Bria E, Vergine M, Zamboni G, Pedron S, Daniele I, Furlanetto J, Carbognin L, Marconi M, Manfrin E, Ibrahim M, Miller K, Tortora G, Molino A, Jasani B, Beccari S, Bonetti F, Chilosi M, Martignoni G, Brunelli M. The identification of a small but significant subset of patients still targetable with anti-HER2 inhibitors when affected by triple negative breast carcinoma. *J Cancer Res Clin Oncol*. 2013 Sep;139(9):1563-8.
143. Pedica F, Ruzzenente A, Bagante F, Capelli P, Cataldo I, Pedron S, Iacono C, Chilosi M, Scarpa A, Brunelli M, Tomezzoli A, Martignoni G, Guglielmi A. A re-emerging marker for

prognosis in hepatocellular carcinoma: the add-value of fishing c-myc gene for early relapse. *PLoS One*. 2013 Jul 10;8(7):e68203.

144. Rosa R, Damiano V, Nappi L, Formisano L, Massari F, Scarpa A, Martignoni G, Bianco R, Tortora G. Angiogenic and signalling proteins correlate with sensitivity to sequential treatment in renal cell cancer. *Br J Cancer*. 2013 Aug 6;109(3):686-93.
145. Righi L, Bollito E, Ceppi P, Mirabelli D, Tavaglione V, Chiusa L, Porpiglia F, Brunelli M, Martignoni G, Terrone C, Papotti M. Prognostic role of bone sialoprotein in clear cell renal carcinoma. *Anticancer Res*. 2013 Jun;33(6):2679-87.
146. Martignoni G. Discovering smoking-related pathway alterations in urothelial cell carcinoma pathogenesis. *Cell Cycle*. 2013 May 15;12(10):1483.
147. Williamson SR, Zhang S, Eble JN, Grignon DJ, Martignoni G, Brunelli M, Wang M, Gobbo S, Baldrige LA, Cheng L. Clear cell papillary renal cell carcinoma- like tumors in patients with von Hippel-Lindau disease are unrelated to sporadic clear cell papillary renal cell carcinoma. *Am J Surg Pathol*. 2013 Aug;37(8):1131-9.
148. Samaratunga H, Martignoni G, Egevad L, Delahunt B. Premalignant lesions of the urinary bladder. *Pathology*. 2013 Apr;45(3):243-50
149. Kuroda N, Tanaka A, Sasaki N, Ishihara A, Matsuura K, Moriyama M, Nagashima Y, Inoue K, Petersson F, Martignoni G, Michal M, Hes O. Review of renal carcinoma with t(6;11)(p21;q12) with focus on clinical and pathobiological aspects. *Histol Histopathol*. 2013 Jun;28(6):685-90.
150. Zheng G, Martignoni G, Antonescu C, Montgomery E, Eberhart C, Netto G, Taube J, Westra W, Epstein JI, Lotan T, Maitra A, Gabrielson E, Torbenson M, Iacobuzio-Donahue C, Demarzo A, Shih IeM, Illei P, Wu TC, Argani P. A broad survey of cathepsin K immunoreactivity in human neoplasms. *Am J Clin Pathol*. 2013 Feb;139(2):151-9.
151. Massari F, Maines F, Modena A, Brunelli M, Bria E, Artibani W, Martignoni G, Tortora G. Castration resistant prostate cancer (CRPC): state of the art, perspectives and new challenges. *Anticancer Agents Med Chem*. 2013 Jul 1;13(6):872-86
152. Kuroda N, Tanaka A, Ohe C, Mikami S, Nagashima Y, Inoue K, Shuin T, Taguchi T, Tominaga A, Alvarado-Cabrero I, Petersson F, Brunelli M, Martignoni G, Michal M, Hes O. Review of renal carcinoid tumor with focus on clinical and pathobiological aspects. *Histol Histopathol*. 2013 Jan;28(1):15-21.